Phosphodiesterase inhibitors in the management of autoimmune disease

Autoimmunity Reviews

Volumn 9, Issue 7, 2010, Pages 511-515

  Shenoy, Padmanabha ^a   Agarwal, Vikas ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti fibrotic; Immunomodulation; Phophodiesterase inhibitors; Pulmonary artery hypertension; Renal protection

Indexed keywords

BLEOMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CILASTAZOL; IBUDILAST; MESOPRAM; METHOTREXATE; MYELIN BASIC PROTEIN; PENCILLAMINE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PROSTACYCLIN DERIVATIVE; ROLIPRAM; SILDENAFIL; TADALAFIL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VARDENAFIL; YM 393059; CYCLIC AMP; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ASTHMA; ALLERGIC ENCEPHALOMYELITIS; ASTHMA; AUTOIMMUNE DISEASE; BUERGER DISEASE; CLINICAL TRIAL; DEMYELINATION; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOMODULATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MACROPHAGE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REGULATORY T LYMPHOCYTE; RENAL PROTECTION; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SKIN FIBROSIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; UBIQUITINATION; UVEITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FIBROSIS; IMMUNOLOGY; KIDNEY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SCLERODERMA, SYSTEMIC; SKIN; VASCULARIZATION;

ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; CYCLIC AMP; FIBROSIS; HUMANS; KIDNEY; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHODIESTERASE INHIBITORS; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 77951877716     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.02.012     Document Type: Review

References (40)

1. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109 (2006) 366-398
2. Smith S.J., Brookes-Fazakerley S., Donnelly L.E., Barnes P.J., Barnette M.S., and Giembycz M.A. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 284 (2003) 279-289
3. Prabhakar U., Lipshutz D., Bartus J.O., et al. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 16 (1994) 805-816
4. Kasyapa C.S., Stentz C.L., Davey M.P., and Carr D.W. Regulation of IL-15-stimulated TNF-alpha production by rolipram. J Immunol 163 (1999) 2836-2843
5. Yamaki K., Li X., Uchida H., et al. Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice. J Pharm Pharmacol 56 (2004) 877-882
6. Kambayashi T., Wallin R.P., and Ljunggren H.G. cAMP-elevating agents suppress dendritic cell function. J Leukoc Biol 70 (2001) 903-910
7. Reyes-Irisarri E., Sánchez A.J., García-Merino J.A., and Mengod G. Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol 66 (2007) 923-931
8. Sommer N., Martin R., McFarland H.F., et al. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J Neuroimmunol 79 (1997) 54-61
9. Genain C.P., Roberts T., Davis R.L., et al. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci 92 (1995) 3601-3605
10. Navikas V., Matusevicius D., Söderström M., et al. The PDE IV inhibitor rolipram in vitro reduces MBP-reactive IFN-γ and TNF-α mRNA expressing blood mononuclear cells in patients with multiple sclerosis. Clin Neuropharm 21 (1998) 236-244
11. Paintlia A.S., Paintlia M.K., Singh I., and Singh A.K. Combined medication of lovastatin with Rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol 214 (2008) 168-180
12. Fujimoto T., Sakoda S., Fujimura H., and Yanagihara T. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 95 (1999) 35-42
13. Rott O., Cash E., and Fleischer B. PDE inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 23 (1993) 1745-1751
14. Zeller E., Stief H.J., Pflug B., et al. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 17 (1984) 188-190
15. Yamamoto S., Sugahara S., Naito R., et al. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo. Eur J Pharmacol 541 (2006) 106-114
16. Yamamoto S., Sugahara S., Ikeda K., and Shimizu Y. Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. Eur J Pharmacol 559 (2007) 219-226
17. Nyman U., Müssener A., Larsson E., Lorentzen J., and Klareskog L. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram. Clin Exp Immunol 108 3 (1997 Jun) 415-419
18. Sekut L., Yarnall D., Stimpson S.A., et al. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 100 (1995) 126-132
19. Yamaki K., Li X., Hossain M.A., and Alam A.H. Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice. Immunol Invest 36 (2007) 131-145
20. Chi Z.L., Hayasaka S., Zhang X.Y., Hayasaka Y., and Cui H.S. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats. Invest Ophthalmol Vis Sci 45 8 (2004) 2497-2502
21. Turner C.R., Andresen C.J., Smith W.B., and Watson J.W. Effects of Rolipram on responses to acute and chronic antigen exposure in monkeys. Am J Respir Crit Care Med 149 (1994) 1153-1159
22. Bopp T., Dehzad N., and Reuter S. Inhibition of cAMP degradation improves regulatory T cell-mediated suppression. J Immunol 182 (2009) 4017-4024
23. Galiè N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
24. Galiè N., Brundage B.H., Ghofrani H.A., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119 22 (2009 Jun 9) 2894-2903
25. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 (2002) 895-900
26. Diller G.P., van Eijl S., Okonko D.O., et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 117 (2008) 3020-3030
27. Wharton J., Strange J.W., Møller G.M., et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 172 (2005) 105-113
28. Fries R., Shariat K., von Wilmowsky H., and Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112 (2005) 2980-2985
29. Shenoy P., Agarwal V., Kumar S., et al. Efficacy of Tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double blind randomized cross over trial. Arth Rheum 58 (2008) S 402
30. Soneja A., Drews M., and Malinski T. Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharmacol Rep 57 (2005) 108-119
31. Senthilkumar A., Smith R.D., Khitha J., et al. Sildenafil promotes ischemia-induced angiogenesis through a PKG-dependent pathway. Arterioscler Thromb Vasc Biol. 27 (2007) 1947-1954
32. Robless P., Mikhailidis D.P., and Stansby G.P. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 23 1 (Jan. 2008) CD003748
33. Tsuboi Y., Shankland S.J., Grande J.P., Walker H.J., Johnson R.J., and Dousa T.P. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. J Clin Invest 98 (1996) 262-270
34. Chen Y.M., Chien C.T., Hu-Tsai M.I., et al. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 56 (1999) 932-943
35. Rodriguez-Iturbe B., Ferrebuz A., Vanegas V., et al. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int 68 (2005) 2131-2142
36. Grover-Páez F., Villegas Rivera G., and Guillén Ortíz R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract 78 (2007) 136-140
37. Hohenstein B., Daniel C., Wittmann S., and Hugo C. PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis. Nephrol Dial Transplant 23 (2008) 3427-3436
38. Hemnes A.R., Zaiman A., and Champion H.C. PDE5A inhibition attenuates bleomycin-induced fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol. 294 (2008) L24-L33
39. Guilluy C., Sauzeau V., Rolli-Derkinderen M., et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 146 (2005) 1010-1018
40. Ferrini M.G., Kovanecz I., Nolazco G., Rajfer J., and Gonzalez-Cadavid N.F. Effects of long-term Vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 97 (2006) 625-633